Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb 19;17(1):54.
doi: 10.1186/s12943-018-0790-4.

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma

Manoj Kumar Kashyap  1   2 , Omar Abdel-Rahman  3
Affiliations
Review

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma

Manoj Kumar Kashyap et al. Mol Cancer. .

Abstract

Esophageal cancer is one of the most common types of cancer, which is a leading cause of cancer-related death worldwide. Based on histological behavior, it is mainly of two types (i) Esophageal squamous cell carcinoma (ESCC), and (ii) esophageal adenocarcinoma (EAD or EAC). In astronomically immense majority of malignancies, receptor tyrosine kinases (RTKs) have been kenned to play a consequential role in cellular proliferation, migration, and metastasis of the cells. The post-translational modifications (PTMs) including phosphorylation of tyrosine (pY) residue of the tyrosine kinase (TK) domain have been exploited for treatment in different malignancies. Lung cancer where pY residues of EGFR have been exploited for treatment purpose in lung adenocarcinoma patients, but we do not have such kind of felicitously studied and catalogued data in ESCC patients. Thus, the goal of this review is to summarize the studies carried out on ESCC to explore the role of RTKs, tyrosine kinase inhibitors, and their pertinence and consequentiality for the treatment of ESCC patients.

Keywords: ALK; AXL; And PDGFR; C-MET; EGFR; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Kinase activity; PTK7; Tyrosine kinase receptor; VEGFR.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Different Receptor Tyrosine Kinases with their respective ligands reported in Esophageal Squamous Cell Carcinoma
See this image and copyright information in PMC

References

    1. Kashyap MK, Marimuthu A, Kishore CJ, Peri S, Keerthikumar S, Prasad TS, Mahmood R, Rao S, Ranganathan P, Sanjeeviah RC, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther. 2009;8:36–46. doi: 10.4161/cbt.8.1.7090. - DOI - PubMed
    1. Testa U, Castelli G, Pelosi E. Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution. Medicines (Basel). 2017;4:67. - PMC - PubMed
    1. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Cancer Netw. 2015;13:194–227. doi: 10.6004/jnccn.2015.0028. - DOI - PubMed
    1. Hunter T. Signaling--2000 and beyond. Cell. 2000;100:113–127. doi: 10.1016/S0092-8674(00)81688-8. - DOI - PubMed
    1. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730–738. doi: 10.1016/j.molcel.2007.11.019. - DOI - PubMed

MeSH terms

Substances